Trial Profile
Efficacy of Rifaximin on Circulating Endotoxins and Cytokines in Patients with Non-Alcoholic Fatty Liver
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Aug 2015
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Pharmacodynamics
- 21 Aug 2015 New trial record